Stellate Ganglia: A Key Therapeutic Target for Malignant Ventricular Arrhythmia in Heart Disease
Circulation Research · 25.04.2025 · 136 (9) · 1049-1069
DOI: 10.1161/circresaha.124.325384 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation Research, erschienen am 25.04.2025. Verfasst von Yu-Long Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine (Y.-L.L., Y.L., H.T., A.J.E.), University of Nebraska Medical Center, Omaha. Hauptthemen laut MEDLINE: Stellate Ganglion, Tachycardia, Ventricular, Ventricular Fibrillation, Heart Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 300 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Malignant ventricular arrhythmias (VAs), such as ventricular tachycardia and ventricular fibrillation, are the cause of approximately half a million deaths per year in the United States, which is a common lethal event in heart disease, such as hypertension, catecholaminergic polymorphic ventricular tachycardia, takotsubo cardiomyopathy, long-QT syndrome, and progressing into advanced heart failure. A common characteristic of these heart diseases, and the subsequent development of VAs, is the overactivation of the sympathetic nervous system. Current treatments for VAs in these heart diseases, such as β-adrenergic receptor blockers and cardiac sympathetic ablation, aim at inhibiting cardiac sympathetic overactivation. However, these treatments do not translate into becoming efficacious as long-term suppressors of ventricular tachycardia/ventricular fibrillation events. As a key regulatory component in the heart, cardiac postganglionic sympathetic neurons residing in the stellate ganglia (SGs) release neurotransmitters (such as norepinephrine and NPY [neuropeptide Y]) to perform their regulatory role in dictating cardiac function. Growing evidence from animal experiments and clinical studies has demonstrated that the remodeling of the SG may be intimately involved in malignant arrhythmogenesis. This identifies the SG as a key potential therapeutic target for the treatment of malignant VAs in heart disease. Therefore, this review summarizes the role of SG in ventricular arrhythmogenesis and updates the novel targeting of SG for clinical treatment of VAs in heart disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine (Y.-L.L., Y.L., H.T., A.J.E.), University of Nebraska Medical Center, Omaha.
- Department of Cellular and Integrated Physiology (Y.-L.L., T.A.P., K.P.P.), University of Nebraska Medical Center, Omaha.
- Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, Vermillion (H.Z.).
ORCID-Profile: Yu-Long Li, Yu Li, Huiyin Tu, Anthony J Evans, Tapan A Patel, Hong Zheng, Kaushik P Patel
Förderung
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Li, Y. L., Li, Y., Tu, H., Evans, A. J., Patel, T. A., Zheng, H., & Patel, K. P. (2025). Stellate Ganglia: A Key Therapeutic Target for Malignant Ventricular Arrhythmia in Heart Disease. Circulation Research, 136(9), 1049-1069. https://doi.org/10.1161/circresaha.124.325384
Vancouver
Li YL, Li Y, Tu H, Evans AJ, Patel TA, Zheng H, et al. Stellate Ganglia: A Key Therapeutic Target for Malignant Ventricular Arrhythmia in Heart Disease. Circulation Research. 2025;136(9):1049-1069. doi:10.1161/circresaha.124.325384
BibTeX
@article{Li2025,
author = {Li, Yu-Long and Li, Yu and Tu, Huiyin and Evans, Anthony J and Patel, Tapan A and Zheng, Hong and Patel, Kaushik P},
title = {Stellate Ganglia: A Key Therapeutic Target for Malignant Ventricular Arrhythmia in Heart Disease},
journal = {Circulation Research},
year = {2025},
volume = {136},
number = {9},
pages = {1049--1069},
doi = {10.1161/circresaha.124.325384}
}
EUVIMED